专题:Cutaneous lymphoproliferative disorders research

This cluster of papers focuses on the classification, staging, treatment, and prognosis of cutaneous lymphomas, with a specific emphasis on mycosis fungoides and Sézary syndrome. It includes discussions on the WHO-EORTC classification, survival outcomes, prognostic factors, and various treatment options such as bexarotene and denileukin diftitox. The cluster also addresses the incidence patterns, genomic landscape, and molecular profiling of cutaneous T-cell lymphomas.
最新文献
Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy

article Full Text OpenAlex

Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma

article Full Text OpenAlex

Dupilumab therapy in atopic dermatitis when cutaneous lymphoma is suspected: Consensus recommendations from the EORTC Cutaneous Lymphoma Tumour Group

article Full Text OpenAlex

Clinical Trial Comparison of Dupilumab and Nemolizumab for Prurigo Nodularis FDA-Approved Biologic Therapy Selection in Prurigo Nodularis

article Full Text OpenAlex

Marginal Zone Lymphoma: 2026 Update on Diagnosis and Management

article Full Text OpenAlex

Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis

article Full Text OpenAlex

Cutaneous T‐cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus

review Full Text OpenAlex

Staphylococcus aureus Augments Epithelial Skin Barrier Damage Through T Cell Activation in Cutaneous T Cell Lymphoma

article Full Text OpenAlex

Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series

article Full Text OpenAlex

Mapping malignant T‐cell states and immune circuits in Sézary syndrome by single‐cell analysis

article Full Text OpenAlex

近5年高被引文献
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

article Full Text OpenAlex 805 FWCI61.3803

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

article Full Text OpenAlex 462 FWCI53.1625

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

article Full Text OpenAlex 403 FWCI27.8017

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial

article Full Text OpenAlex 294 FWCI23.3787

Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials

article Full Text OpenAlex 254 FWCI57.1228

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

article Full Text OpenAlex 244 FWCI18.3291

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023

article Full Text OpenAlex 194 FWCI43.6766

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

article Full Text OpenAlex 192 FWCI19.2626

Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States

article Full Text OpenAlex 189 FWCI14.6218

Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials

article Full Text OpenAlex 173 FWCI20.8134